Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

New England Journal of Medicine

Volumn 337, Issue 23, 1997, Pages 1641-1647

  Delmas, Pierre D ^a   Bjarnason, Nina H ^b   Mitlak, Bruce H ^c   Ravoux, Anne Catherine ^a   Shah, Aarti S ^c   Huster, William J ^c   Draper, Michael ^c   Christiansen, Claus ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIOPHENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; RALOXIFENE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERUS;

BONE DENSITY; CHOLESTEROL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; ENDOMETRIUM; ESTROGEN ANTAGONISTS; FEMALE; HIP JOINT; HOT FLASHES; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PIPERIDINES; POSTMENOPAUSE; RALOXIFENE;

EID: 0030664688     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199712043372301     Document Type: Article

References (31)

1. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.
2. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-61.
3. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
4. Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 1983;32:2869-75.
5. Anzano MA, Peer CW, Smith JM, et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1996;88:123-5.
6. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-9.
7. Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 1994;135:2001-5.
8. Draper MW, Boss SM, Huster WJ, Neild JA. Effects of raloxifene hydrochloride on serum markers of bone and lipid metabolism - dose-response relationships. Calcif Tissue Int 1994;54:339. abstract.
9. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11:835-42.
10. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 1996;273:1222. [Erratum, Science 1997;275: 1249.]
11. Garnero P, Grimaux M, Demiaux B, Preaudat C, Sequin P, Delmas PD. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res 1992;7:1389-98.
12. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-53.
13. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40:2022-5.
14. Armitage P, McPherson CK, Rowe BC. Repeated significance tests on accumulating data. J R Stat Soc [A] 1969;132:235-44.
15. Shao J. Consistency of jackknife variance estimators. Statistics 1996; 22:49-57.
16. Efron B, Stein C. The jackknife estimate of variance. Ann Stat 1981; 9:586-96.
17. Garnero P, Sornay-Rendu K, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11:337-49.
18. Hosking DJ, McClung MR, Ravn P, et al. Alendronate in the prevention of osteoporosis: EPIC study two-year results. J Bone Miner Res 1996; 11:Suppl 1:S133. abstract.
19. Heaney RP, Draper MW. Raloxifene and estrogen: comparative bone remodeling kinetics. J Clin Endocrinol Metab 1997;82:3425-9.
20. Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995;17:383-90.
21. Harris ST, Watts NB, Jackson RD, et al. Four year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95:557-67.
22. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 1995;99:636-41.
23. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14:78-84.
24. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208. [Erratum, JAMA 1995;274:1676.]
25. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993; 153:2209-16.
26. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
27. Miettinen M, Turpeinen O, Karvonen MJ, Elosuo R, Paavilainen E. Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes: a twelve-year clinical trial in men and women. Lancet 1972;2:835-8.
28. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffmann R, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 1997;96:1964-9.
29. Boss SM, Huster WJ, Neild JA, Giant M, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol (in press).
30. Cohen I, Rosen DJ, Shapira J, et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 1994;52: 185-90.
31. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994;343:1318-21.